Author: Nichols Martin|| Date Published: September 28, 2018
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
IBM (NYSE: IBM), Acumen, Dovel Technologiesand IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.
FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.
The indefinite delivery/indefinite quantity contracts have a five-year ordering period.
The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.
Brian Meyer, federal field chief technology officer at Axonius Federal, said cybersecurity asset management could help government agencies make dozens…
“Technology transformation company Red River has acquired Invictus International Consulting to expand its cybersecurity and enterprise modernization capabilities to support…
Synergy ECP, a software engineering, cybersecurity and systems engineering services provider, has acquired NetServices, a company offering secure, mission-focused technology services. The…
Precision Aerospace & Defense Group and FACT II Acquisition, a special purpose acquisition company, have signed a definitive business combination agreement to…
LMI has announced the acquisition of intellectual property and advanced capabilities to broaden its in-transit visibility and asset tracking services for…
The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.
